Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:27:53 EST Sat 13 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Z:AIM - AIM IMMUNOTECH INC - https://www.aerosonic.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AIM - Z0.21.19·1.590.11.37-0.11-7.455.8681871.38  1.4299  1.3425.40  1.2619:41:23Dec 1015 min RT 2¢

Recent Trades - Last 10 of 187
Time ETExPriceChangeVolume
19:41:23Z1.40-0.05800
17:50:32Z1.365-0.08535
17:50:32Z1.40-0.0560
17:01:23Z1.4132-0.036850
16:22:14Z1.41-0.0448
16:10:03Z1.37-0.081
16:04:00Z1.37-0.081
16:02:13Z1.39-0.065
15:59:50Z1.34-0.11101
15:56:42Z1.35-0.10100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-10 09:00U:AIMNews ReleaseAIM ImmunoTech Announces Release of the Next CEO Corner Segment
2025-12-01 08:55U:AIMNews ReleaseAIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series
2025-11-18 08:55U:AIMNews ReleaseAIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
2025-11-10 08:55U:AIMNews ReleaseAIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
2025-11-04 09:05U:AIMNews ReleaseAIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
2025-11-03 08:55U:AIMNews ReleaseAIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen(TM) (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
2025-10-20 09:15U:AIMNews ReleaseAIM ImmunoTech to Attend the 2025 Maxim Growth Summit
2025-09-25 08:45U:AIMNews ReleaseAIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen(TM) (Rintatolimod) with Checkpoint Inhibitors
2025-09-22 09:00U:AIMNews ReleaseAIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
2025-09-04 11:00U:AIMNews ReleaseAIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
2025-08-21 09:00U:AIMNews ReleaseAIM ImmunoTech Announces Release of the Next CEO Corner Segment
2025-08-15 09:00U:AIMNews ReleaseAIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-14 08:55U:AIMNews ReleaseAIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
2025-08-06 09:00U:AIMNews ReleaseAIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
2025-08-04 09:00U:AIMNews ReleaseAIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen(TM) Clinical Development Toward Pancreatic Cancer Approval
2025-07-31 09:00U:AIMNews ReleaseAIM ImmunoTech Announces Closing of $8.0 Million Public Offering
2025-07-29 09:00U:AIMNews ReleaseAIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
2025-07-28 09:00U:AIMNews ReleaseAIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen(TM) (rintatolimod) in Combination with AstraZeneca's Imfinzi(TM) (durvalumab) for the Treatment of Pancreatic Cancer
2025-07-02 08:55U:AIMNews ReleaseAIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
2025-06-20 16:15U:AIMNews ReleaseAIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements